nejm semaglutide heart failure Updates in Medicine | 🩺 Oral Cuts CV Risk in High-Risk T2DM – SOUL Trial (NEJM, Mar 2025) 🔗 Original article link in bio 📌 Key Highlights: 🔹 New in the May 29,

However, because of the small number of suicidal thoughts or actions observed in both people using GLP-1 RAs and in the comparative control groups, the FDA cannot definitively rule out that a small risk may exist

One study from researchers at the University of Utah suggests the loss of strength is largely the result of not eating enough calories

Deprotect with 200mLx2DBLK for 5min+7min, and wash with 200mLx5DMF

Clinical data shows weight loss typically plateaus around 60 weeks, roughly 14 months into treatment

Semaglutide's appearance varies across its different formulations, each designed for specific therapeutic indications and administration routes

Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants